COX-2 selectivity varies  across class

Leslie G Cleland,* Michael J James^†

Department of Rheumatology, Royal Adelaide Hospital, North Terrace, Adelaide, SA 5000 lclelandATmail.rah.sa.gov.au

Correspondence:

1. Langton PE, Hankey GJ, Eikelboom JW. Cardiovascular safety of rofecoxib (Vioxx): lessons learned and unanswered questions [editorial]. Med J Aust 2004; 181: 524-525. Previously published online, 26 October 2004. <MJA full text>
2. Cleland LG, James MJ, Stamp LK, Penglis PS. COX-2 inhibition and thrombotic tendency: a need for surveillance. Med J Aust 2001; 175: 214-217.
3. Patrono C, Patrignani P, Garcia-Rodriguez LA. Cyclooxygenase-selective inhibition of prostanoid formation: transducing biochemical selectivity into clinical read-outs. J Clin Invest 2001; 108: 7-13.
4. Juni P, Rutjes AWS, Dieppe PA. Are selective COX-2 inhibitors superior to traditional non-steroidal anti-inflammatory drugs? BMJ 2002; 324: 1287-1288.
5. Pfizer provides information to healthcare professionals about its Cox-2 medicine Bextra® (Valdecoxib) [press release]. 15 October 2004. Available at: www.pfizer.com/are/news_releases/2004pr/mn_2004_1015.html (accessed Nov 2004).
6. James MJ, Cleland LG. Applying a research ethics committee approach to a medical practice controversy: the case of COX-2 inhibitors. J Med Ethics 2004; 30: 182-184.
7. Kumana CR, Cheung BM, Lauder IJ. Gauging the impact of statins using number needed to treat. JAMA 1999; 282: 1899-1901.

Online responses are no longer available. Please refer to our instructions for authors page for more information.